REGV131 LNP1265
Alternative Names: REGV 131 LNP 1265Latest Information Update: 03 May 2024
At a glance
- Originator Intellia Therapeutics
- Developer Intellia Therapeutics; Regeneron Pharmaceuticals
- Class Antihaemorrhagics; Blood coagulation factors; Gene therapies
- Mechanism of Action Factor IX replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Haemophilia B
Most Recent Events
- 23 Apr 2024 Regeneron Pharmaceuticals plans the phase-I/II BEYOND-9 trial for Haemophilia B (In children, In adolescents, In adults) in July 2024 (IV) (NCT06379789)
- 22 Feb 2024 US FDA approves IND application for gene editing therapeutics in Haemophilia B
- 22 Feb 2024 Intellia Therapeutics and Regeneron plans a first-in-human phase I trial for Haemophilia B in mid-2024